The MalaYsian GestatiOnal Diabetes and Prevention of DiabetES Study (MyGODDESS)
Primary Purpose
Gestational Diabetes, GDM, Pregnancy-Induced Diabetes
Status
Recruiting
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
MyManis app
Sponsored by
About this trial
This is an interventional supportive care trial for Gestational Diabetes
Eligibility Criteria
Inclusion Criteria:
- aged above 18 years,
- diagnosed with GDM defined using fasting blood glucose > 5.1mmol/1 or 2-hour postprandial >7.8mmol/1 which are the standard guidelines for diagnosis of GDM in Malaysia,
- permanent resident in the state of Selangor,
- registered in one of the study health clinics
- owning a smartphone (iOS 11 or Android 7) with internet connection,
- able to speak, read, and understand English and/or Malay.
Exclusion Criteria:
- are having a twin pregnancy,
- have type 1 or 2 diabetes,
- have severe physical disability that would prevent any increased uptake of physical exercise,
- have severe mental illness (psychosis, bipolar, substance dependence or active suicidal ideation),
- are currently participating in a weight loss program or diabetes prevention intervention.
Sites / Locations
- Klinik Kesihatan Puchong Batu 14Recruiting
- Klinik Kesihatan Seri KembanganRecruiting
- Klinik Kesihatan Putrajaya Presint 9Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Intervention arm
Control arm
Arm Description
Women who meet study inclusion criteria and consent to study participation will be randomised using sealed envelope randomisation and online database for clinical trials to one of two groups in a 1:1 ratio.
Women allocated to the control arm will receive standard care and no digital intervention. This includes self-monitoring blood glucose and lifestyle advice (diet, physical activity, optimal body weight) by a multidisciplinary team.
Outcomes
Primary Outcome Measures
Number of women who were randomised to the treatment groups.
The proportion of women who were randomised (numerator) out of those identified from the clinical registers (study population as denominator)
Number of women that take up the intervention
The proportion of women who take up the intervention (numerator) out of those in the intervention arm (denominator)
Number of women that take up the intervention
The proportion of women who take up the intervention (numerator) out of those in the intervention arm (denominator)
Number of women that take up the intervention
The proportion of women who take up the intervention (numerator) out of those in the intervention arm (denominator)
Number of women withdrawn or loss to follow up
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Number of women withdrawn or loss to follow up
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Number of women withdrawn or loss to follow up
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Number of women withdrawn or loss to follow up
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Number of women withdrawn or loss to follow up
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Secondary Outcome Measures
Number of women consented
The proportion of women who give consent for screening eligibility (numerator) out of those identified from clinical registers (denominator)
Number of women randomised
The proportion of women who were randomised (numerator) out of those eligible to participate (denominator)
Number of women completed the secondary outcomes
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Number of women completed the secondary outcomes
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Number of women completed the secondary outcomes
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Number of women completed the secondary outcomes
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Number of women completed the secondary outcomes
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Number of women randomised
The number of women randomised per month overall, and per month per study site.
Full Information
NCT ID
NCT05204706
First Posted
October 31, 2021
Last Updated
November 1, 2022
Sponsor
Universiti Putra Malaysia
Collaborators
King's College London, Ministry of Education, Malaysia, Ministry of Health, Malaysia
1. Study Identification
Unique Protocol Identification Number
NCT05204706
Brief Title
The MalaYsian GestatiOnal Diabetes and Prevention of DiabetES Study
Acronym
MyGODDESS
Official Title
A Feasibility Randomised Controlled Trial of a Mobile Phone Application for the Primary Prevention of Type 2 Diabetes in Malaysian Women With Gestational Diabetes Mellitus.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 24, 2022 (Actual)
Primary Completion Date
April 2023 (Anticipated)
Study Completion Date
April 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Putra Malaysia
Collaborators
King's College London, Ministry of Education, Malaysia, Ministry of Health, Malaysia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Gestational diabetes mellitus (GDM) is an increasingly common condition of pregnancy and is associated with adverse foetal, infant, and maternal outcomes. Over 50% of women with history of GDM will develop type 2 diabetes (T2D) in later life. Asian women experience disproportionate risk of both GDM and T2D compared to women from other ethnic groups. Lifestyle interventions have been proven to be effective in preventing progression to T2DM in high-risk populations. This is a two-arm, parallel feasibility RCT. Sixty Malaysian women with GDM will be randomized to receive the intervention or standard care in the antenatal period to 12 months postpartum. The intervention is a diabetes prevention intervention delivered via a smartphone application developed based on the Information-Motivation-Behavioral Skills (IMB) model of behavior change and group support utilizing motivational interviewing, which will provide women with tailored information and support to encourage weight loss through adapted dietary intake and physical activity. Women in the control arm will receive standard care.
Detailed Description
Gestational diabetes mellitus (GDM) is a global health challenge, with rates increasing around the world. The adverse short and long-term health outcomes of GDM for both mother and their offspring have been well established. In the long-terms women are up to ten times more likely to develop T2D after GDM and approximately 50% of mothers with GDM will develop diabetes within 10 years. Considerable evidence from several landmark studies has shown that healthy lifestyle interventions and behaviour change can delay or even prevent the onset of T2D in high-risk populations. Given women with prior GDM are at high risk of developing T2D earlier in their lifespan than women with normoglycemic pregnancies, intervening early with an effective diabetes prevention intervention offers a unique window of opportunity along the life-course for the prevention of T2D for the mother. Mobile health (mHealth) is a rapidly growing field of public health, defined as the use of mobile phones and other wireless technology to support the achievement of health objectives. Due to the increasing ownership rate of smartphones, significant numbers of mHealth applications 'apps' have been developed. Pregnant and postpartum women are increasingly utilising such technologies as sources of health information and services for pregnancy self-care and infant care.
The overall aim of the RCT is to test the feasibility of undertaking a definitive trial of a diabetes prevention intervention delivered via a smartphone app over 15-months in women with GDM from randomisation in the antenatal period to 12 months postpartum.
Sixty participants will be recruited from three public health clinics within the southern Selangor state of Malaysia. Women will be eligible for recruitment if they meet the following criteria: i) aged above 18 years, ii) diagnosed with GDM defined using fasting blood glucose > 5.1mmol/1 or 2-hour postprandial >7.8mmol/1 which are the standard guidelines for diagnosis of GDM in Malaysia, iii) permanent resident in the state of Selangor, iv) registered in one of the study health clinics v) owning a smartphone (iOS 11 or Android 7), vi) able to speak, read, and understand English and/or Malay. Women will be excluded if they meet any of the following criteria: i) are having a twin pregnancy, ii) have type 1 or 2 diabetes, iii) have severe physical disability that would prevent any increased uptake of physical exercise, iv) have severe mental illness (psychosis, bipolar, substance dependence or active suicidal ideation), v) are currently participating in a weight loss program or diabetes prevention intervention.
Women who meet study inclusion criteria and consent to study participation will be randomised to either the intervention or control arm. The intervention consists of a smartphone app for women with GDM called MyManis (the English meaning of MyManis is 'my sweet (baby)' and a virtual peer support group. The development of the app was guided by the Information-Motivation-Behavioural Skills (IMB) model of behaviour change. The MyManis app aims to provide women with information and support and motivation to act on this information to make lifestyle behaviour changes in diet and physical activity from pregnancy to post-partum. The app is available for women in both Malay and English. Women allocated to the control arm will receive standard care and no digital intervention.
The overall aim of the RCT is to test the feasibility of undertaking a definitive trial of a diabetes prevention intervention including a smartphone app and group support over 15-months in women with GDM from randomization in the antenatal period to 12 months postpartum.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes, GDM, Pregnancy-Induced Diabetes
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention arm
Arm Type
Active Comparator
Arm Description
Women who meet study inclusion criteria and consent to study participation will be randomised using sealed envelope randomisation and online database for clinical trials to one of two groups in a 1:1 ratio.
Arm Title
Control arm
Arm Type
No Intervention
Arm Description
Women allocated to the control arm will receive standard care and no digital intervention. This includes self-monitoring blood glucose and lifestyle advice (diet, physical activity, optimal body weight) by a multidisciplinary team.
Intervention Type
Other
Intervention Name(s)
MyManis app
Intervention Description
The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
Primary Outcome Measure Information:
Title
Number of women who were randomised to the treatment groups.
Description
The proportion of women who were randomised (numerator) out of those identified from the clinical registers (study population as denominator)
Time Frame
Collected antenatally at 30 weeks pregnancy
Title
Number of women that take up the intervention
Description
The proportion of women who take up the intervention (numerator) out of those in the intervention arm (denominator)
Time Frame
Collected antenatally at 36 weeks pregnancy
Title
Number of women that take up the intervention
Description
The proportion of women who take up the intervention (numerator) out of those in the intervention arm (denominator)
Time Frame
Collected antenatally at 6 months after delivery.
Title
Number of women that take up the intervention
Description
The proportion of women who take up the intervention (numerator) out of those in the intervention arm (denominator)
Time Frame
Collected antenatally at 12 months after delivery.
Title
Number of women withdrawn or loss to follow up
Description
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 36 weeks pregnancy
Title
Number of women withdrawn or loss to follow up
Description
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 3 months after delivery
Title
Number of women withdrawn or loss to follow up
Description
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 6 months after delivery
Title
Number of women withdrawn or loss to follow up
Description
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 9 months after delivery
Title
Number of women withdrawn or loss to follow up
Description
The proportion of women who are withdrawn or lost to follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 12 months after delivery
Secondary Outcome Measure Information:
Title
Number of women consented
Description
The proportion of women who give consent for screening eligibility (numerator) out of those identified from clinical registers (denominator)
Time Frame
Collected antenatally at 24-28 weeks pregnancy
Title
Number of women randomised
Description
The proportion of women who were randomised (numerator) out of those eligible to participate (denominator)
Time Frame
Collected antenatally at 24-28 weeks pregnancy
Title
Number of women completed the secondary outcomes
Description
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 36 weeks pregnancy
Title
Number of women completed the secondary outcomes
Description
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 3 months after delivery
Title
Number of women completed the secondary outcomes
Description
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 6 months after delivery
Title
Number of women completed the secondary outcomes
Description
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 9 months after delivery
Title
Number of women completed the secondary outcomes
Description
The proportion of those who completed the secondary outcomes at follow-up (numerator) out of those randomised (denominator)
Time Frame
Collected antenatally at 12 months after delivery
Title
Number of women randomised
Description
The number of women randomised per month overall, and per month per study site.
Time Frame
Collected antenatally at 30 weeks pregnancy
Other Pre-specified Outcome Measures:
Title
Body weight at T0
Description
Weight (kg)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Body weight at T1
Description
Weight (kg)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Body weight at T2
Description
Weight (kg)
Time Frame
Collected antenatally at T2: 3 months after delivery
Title
Body weight at T3
Description
Weight (kg)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Body weight at T4
Description
Weight (kg)
Time Frame
Collected antenatally at T4: 9 months after delivery
Title
Body weight at T5
Description
Weight (kg)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Height at T0
Description
measured for 1 time only (in centimetres, cm)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Body mass index at T0
Description
calculated as body weight divided by (heightxheight) (kg/m^2)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Body mass index at T1
Description
calculated as body weight divided by (heightxheight) (kg/m^2)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Body mass index at T2
Description
calculated as body weight divided by (heightxheight) (kg/m^2)
Time Frame
Collected antenatally at T2: 3 months after delivery
Title
Body mass index at T3
Description
calculated as body weight divided by (heightxheight) (kg/m^2)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Body mass index at T4
Description
calculated as body weight divided by (heightxheight) (kg/m^2)
Time Frame
Collected antenatally at T4: 9 months after delivery
Title
Body mass index at T5
Description
calculated as body weight divided by (heightxheight) (kg/m^2)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Body fat percentage at T0
Description
Body fat percentage reported in % (to 1 decimal point)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Body fat percentage at T1
Description
Body fat percentage reported in % (to 1 decimal point)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Body fat percentage at T2
Description
Body fat percentage reported in % (to 1 decimal point)
Time Frame
Collected antenatally at T2: 3 months after delivery
Title
Body fat percentage at T3
Description
Body fat percentage reported in % (to 1 decimal point)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Body fat percentage at T4
Description
Body fat percentage reported in % (to 1 decimal point)
Time Frame
Collected antenatally at T4: 9 months after delivery
Title
Body fat percentage at T5
Description
Body fat percentage reported in % (to 1 decimal point)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Blood pressure reading at T0
Description
measure systolic and diastolic blood pressure (mmHg)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Blood pressure reading at T1
Description
measure systolic and diastolic blood pressure (mmHg)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Blood pressure reading at T3
Description
measure systolic and diastolic blood pressure (mmHg)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Blood pressure reading at T5
Description
measure systolic and diastolic blood pressure (mmHg)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Total Cholestrol at T0
Description
Total Cholestrol (mmol/L)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Total Cholestrol at T1
Description
Total Cholestrol (mmol/L)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Total Cholestrol at T3
Description
Total Cholestrol (mmol/L)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Total Cholestrol at T5
Description
Total Cholestrol (mmol/L)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Low Density Lipoprotein Cholestrol at T0
Description
Low Density Lipoprotein Cholestrol, LDL (mmol/L)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Low Density Lipoprotein Cholestrol at T1
Description
Low Density Lipoprotein Cholestrol, LDL (mmol/L)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Low Density Lipoprotein Cholestrol at T3
Description
Low Density Lipoprotein Cholestrol, LDL (mmol/L)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Low Density Lipoprotein Cholestrol at T5
Description
Low Density Lipoprotein Cholestrol, LDL (mmol/L)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
High Density Lipoprotein cholesterol at T0
Description
High Density Lipoprotein cholesterol, HDL (mmol/L)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
High Density Lipoprotein cholesterol at T1
Description
High Density Lipoprotein cholesterol, HDL (mmol/L)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
High Density Lipoprotein cholesterol at T3
Description
High Density Lipoprotein cholesterol, HDL (mmol/L)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
High Density Lipoprotein cholesterol at T5
Description
High Density Lipoprotein cholesterol, HDL (mmol/L)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
HbA1c at T0
Description
HbA1c (%)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
HbA1c at T1
Description
HbA1c (%)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
HbA1c at T3
Description
HbA1c (%)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
HbA1c at T5
Description
HbA1c (%)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Fasting blood glucose at T0
Description
Fasting blood glucose (mmol/l)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Fasting blood glucose at T1
Description
Fasting blood glucose (mmol/l)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Oral glucose tolerance test (OGTT) Fasting at T3
Description
Oral glucose tolerance test (OGTT) Fasting (mmol/l)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Oral glucose tolerance test (OGTT) Fasting at T5
Description
Oral glucose tolerance test (OGTT) Fasting (mmol/l)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Oral glucose tolerance test (OGTT) 2-hour Postprandial at T3
Description
Oral glucose tolerance test (OGTT) 2-hour Postprandial (mmol/l)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Oral glucose tolerance test (OGTT) 2-hour Postprandial at T5
Description
Oral glucose tolerance test (OGTT) 2-hour Postprandial (mmol/l)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Fasting Serum Insulin at T0
Description
Fasting Serum Insulin (U/mL)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Fasting Serum Insulin at T1
Description
Fasting Serum Insulin (U/mL)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Fasting Serum Insulin at T3
Description
Fasting Serum Insulin (U/mL)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Fasting Serum Insulin at T5
Description
Fasting Serum Insulin (U/mL)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Insulin resistance at T0
Description
Insulin resistance (HOMA-IR)
Time Frame
Collected antenatally at T0: 30 weeks pregnancy
Title
Insulin resistance at T1
Description
Insulin resistance (HOMA-IR)
Time Frame
Collected antenatally at T1: 36 weeks pregnancy
Title
Insulin resistance at T3
Description
Insulin resistance (HOMA-IR)
Time Frame
Collected antenatally at T3: 6 months after delivery
Title
Insulin resistance at T5
Description
Insulin resistance (HOMA-IR)
Time Frame
Collected antenatally at T5: 12 months after delivery
Title
Total score for Self-efficacy for exercise at T0
Description
This scale consist of 18 items whereby the response options are ranging from 0-100, ranging in 10-unit intervals from 0 (cannot do); through intermediate degrees of assurance, 50 (moderately certain can do); to complete assurance, 100 (highly certain can do). The scale is scored by summing the numerical ratings for each response and dividing by the number of responses. Higher scores indicates higher self-efficacy for exercise.
Time Frame
Collected at T0: 30 weeks pregnancy
Title
Total score for Self-efficacy for exercise at T3
Description
This scale consist of 18 items whereby the response options are ranging from 0-100, ranging in 10-unit intervals from 0 (cannot do); through intermediate degrees of assurance, 50 (moderately certain can do); to complete assurance, 100 (highly certain can do). The scale is scored by summing the numerical ratings for each response and dividing by the number of responses. Higher scores indicates higher self-efficacy for exercise.
Time Frame
Collected at T3: 6 months after delivery
Title
Total score for Self-efficacy for exercise at T5
Description
This scale consist of 18 items whereby the response options are ranging from 0-100, ranging in 10-unit intervals from 0 (cannot do); through intermediate degrees of assurance, 50 (moderately certain can do); to complete assurance, 100 (highly certain can do). The scale is scored by summing the numerical ratings for each response and dividing by the number of responses. Higher scores indicates higher self-efficacy for exercise.
Time Frame
Collected at T5: 12 months after delivery
Title
Mother-infant relationship at T0
Description
The mother-infant relationship will be assessed using the Maternal Antenatal Attachment Scale which comprises 19 items with response options presented on a 5-point Likert scale. A total score is obtained by summing the responses to the 19 items, resulting in a possible scoring range of 19 to 95. Higher scores are indicative of stronger attachment.
Time Frame
Collected at 30 weeks pregnancy
Title
Mother-infant relationship at T3
Description
The mother-infant relationship will be assessed using the Maternal Antenatal Attachment Scale which comprises 19 items with response options presented on a 5-point Likert scale. A total score is obtained by summing the responses to the 19 items, resulting in a possible scoring range of 19 to 95. Higher scores are indicative of stronger attachment.
Time Frame
Collected at 6 months after delivery
Title
Mother-infant relationship at T5
Description
The mother-infant relationship will be assessed using the Maternal Antenatal Attachment Scale which comprises 19 items with response options presented on a 5-point Likert scale. A total score is obtained by summing the responses to the 19 items, resulting in a possible scoring range of 19 to 95. Higher scores are indicative of stronger attachment.
Time Frame
Collected at 12 months after delivery
Title
Depressive symptoms at T0
Description
The questionnaire consist of 10 items. Add up all checked (Tick) boxes on PHQ-9. For every tick boxes: the score indicated is as below: 0= Not at all; 1=Several days; 2=More than half the days; 3=Nearly every day. Then add the subtotal to produce a total score. The possible range score is 0-27.
Time Frame
Collected at T0: 30 weeks pregnancy
Title
Depressive symptoms at T3
Description
The questionnaire consist of 10 items. Add up all checked (Tick) boxes on PHQ-9. For every tick boxes: the score indicated is as below: 0= Not at all; 1=Several days; 2=More than half the days; 3=Nearly every day. Then add the subtotal to produce a total score. The possible range score is 0-27.
Time Frame
Collected at T3: 6 months after delivery
Title
Depressive symptoms at T5
Description
The questionnaire consist of 10 items. Add up all checked (Tick) boxes on PHQ-9. For every tick boxes: the score indicated is as below: 0= Not at all; 1=Several days; 2=More than half the days; 3=Nearly every day. Then add the subtotal to produce a total score. The possible range score is 0-27.
Time Frame
Collected at T5: 12 months after delivery
Title
Dietary intake at T0
Description
Total macronutrient intake from standardised multiple-pass 24-hour dietary recall)
Time Frame
Collected at T0: 30 weeks pregnancy
Title
Dietary intake at T3
Description
Total macronutrient intake from standardised multiple-pass 24-hour dietary recall)
Time Frame
Collected at T3: 6 months after delivery
Title
Dietary intake at T5
Description
Total macronutrient intake from standardised multiple-pass 24-hour dietary recall)
Time Frame
Collected at T5: 12 months after delivery
Title
Physical activity at T0
Description
The questionnaire consist of 7 items. The total score will be reported as a continuous measure and reported as median METminutes. Median values can be computed for walking (W), moderate-intensity activities (M), and vigorous-intensity activities (V) using the following formulas:
MET values and Formula for computation of Met-minutes Walking MET-minutes/week = 3.3 * walking minutes * walking days Moderate MET-minutes/week = 4.0 * moderate-intensity activity minutes * moderate days Vigorous MET-minutes/week = 8.0 * vigorous-intensity activity minutes * vigorous-intensity days A combined total physical activity MET-min/week can be computed as the sum of Walking + Moderate + Vigorous MET-min/week scores.
Time Frame
Collected at T0: 30 weeks pregnancy
Title
Physical activity at T3
Description
The questionnaire consist of 7 items. The total score will be reported as a continuous measure and reported as median METminutes. Median values can be computed for walking (W), moderate-intensity activities (M), and vigorous-intensity activities (V) using the following formulas:
MET values and Formula for computation of Met-minutes Walking MET-minutes/week = 3.3 * walking minutes * walking days Moderate MET-minutes/week = 4.0 * moderate-intensity activity minutes * moderate days Vigorous MET-minutes/week = 8.0 * vigorous-intensity activity minutes * vigorous-intensity days A combined total physical activity MET-min/week can be computed as the sum of Walking + Moderate + Vigorous MET-min/week scores.
Time Frame
Collected at T3: 6 months after delivery
Title
Physical activity at T5
Description
The questionnaire consist of 7 items. The total score will be reported as a continuous measure and reported as median METminutes. Median values can be computed for walking (W), moderate-intensity activities (M), and vigorous-intensity activities (V) using the following formulas:
MET values and Formula for computation of Met-minutes Walking MET-minutes/week = 3.3 * walking minutes * walking days Moderate MET-minutes/week = 4.0 * moderate-intensity activity minutes * moderate days Vigorous MET-minutes/week = 8.0 * vigorous-intensity activity minutes * vigorous-intensity days A combined total physical activity MET-min/week can be computed as the sum of Walking + Moderate + Vigorous MET-min/week scores.
Time Frame
Collected at T5: 12 months after delivery
Title
mean step count at T0
Description
Number of steps in inbuild smartphone app
Time Frame
Collected at T0: 30 weeks pregnancy
Title
mean step count at T3
Description
Number of steps in inbuild smartphone app
Time Frame
Collected at T3: 6 months after delivery
Title
mean step count at T5
Description
Number of steps in inbuild smartphone app
Time Frame
Collected at T5: 12 months after delivery
Title
Infant feeding T3
Description
Type of feeding status
Time Frame
Collected at T3: 6 months after delivery
Title
Infant feeding at T5
Description
Type of feeding status
Time Frame
Collected at T5: 12 months after delivery
Title
Alcohol intake at T0
Description
Frequency of intake
Time Frame
Collected at T0: 30 weeks pregnancy
Title
Alcohol intake at T3
Description
Frequency of intake
Time Frame
Collected at T3: 6 months after delivery
Title
Alcohol intake at T5
Description
Frequency of intake
Time Frame
Collected at T5: 12 months after delivery
Title
Smoking status at T0
Description
type of smoker
Time Frame
Collected at T0: 30 weeks pregnancy
Title
Smoking status at T3
Description
type of smoker
Time Frame
Collected at T3: 6 months after delivery
Title
Smoking status at T5
Description
type of smoker
Time Frame
Collected at T5: 12 months after delivery
Title
Recruitment rate
Description
number of eligible, consented, screened, enrolled, and randomised
Time Frame
Collected at 30 weeks pregnancy
Title
T1 Dosage delivered - app download
Description
The number of MyManis app delivered by the researcher and the number of app downloads (n) by the participant.
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T3 Dosage delivered - app download
Description
The number of MyManis app delivered by the researcher and the number of app downloads (n) by the participant.
Time Frame
Collected at T3: 6 months after delivery
Title
T5 Dosage delivered - app download
Description
The number of MyManis app delivered by the researcher and the number of app downloads (n) by the participant.
Time Frame
Collected at T5: 12 months after delivery
Title
T1 Dosage delivered - Support group
Description
Total number of group support sessions (n) planned to deliver by the dietitian train in motivational interviewing.
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T3 Dosage delivered - Support group
Description
Total number of group support sessions (n) planned to deliver by the dietitian train in motivational interviewing.
Time Frame
Collected at T3: 6 months after delivery
Title
T5 Dosage delivered - Support group
Description
Total number of group support sessions (n) planned to deliver by the dietitian train in motivational interviewing.
Time Frame
Collected at T5: 12 months after delivery
Title
T1 Dosage received - Participant's engagement
Description
The number of participant log into MyManis app per month (n)
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T3 Dosage received - Participant's engagement
Description
The number of participant log into MyManis app per month (n)
Time Frame
Collected at T3: 6 months after delivery
Title
T5 Dosage received - Participant's engagement
Description
The number of participant log into MyManis app per month (n)
Time Frame
Collected at T5: 12 months after delivery
Title
T1 Dosage received - length of log in
Description
This is an extent to which participant's engagement through length of participant log into MyManis app (hours and minutes)
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T3 Dosage received - length of log in
Description
This is an extent to which participant's engagement through length of participant log into MyManis app (hours and minutes)
Time Frame
Collected at T3: 6 months after delivery
Title
T5 Dosage received - length of log in
Description
This is an extent to which participant's engagement through length of participant log into MyManis app (hours and minutes)
Time Frame
Collected at T5: 12 months after delivery
Title
T1 Dosage received - time spent on DIET component
Description
Participant time spent on DIET component (hours and minutes)
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T1 Dosage received - time spent on EXERCISE component
Description
Participant time spent on EXERCISE component (hours and minutes)
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T1 Dosage received - time spent on MENTAL HEALTH component
Description
Participant time spent on MENTAL HEALTH component (hours and minutes)
Time Frame
Collected at T1: 36 weeks pregnancy
Title
T3 Dosage received - time spent on DIET component
Description
Time spent on DIET component (hours and minutes)
Time Frame
Collected at T3: 6months after delivery
Title
T3 Dosage received - time spent on EXERCISE component
Description
Time spent on EXERCISE component (hours and minutes)
Time Frame
Collected at T3: 6months after delivery
Title
T3 Dosage received - time spent on MENTAL HEALTH component
Description
Time spent on MENTAL HEALTH component (hours and minutes)
Time Frame
Collected at T3: 6months after delivery
Title
T5 Dosage received - time spent on DIET component
Description
Time spent on DIET component (hours and minutes)
Time Frame
Collected at T5: 12 months after delivery
Title
T5 Dosage received - time spent on EXERCISE component
Description
Time spent on EXERCISE component (hours and minutes)
Time Frame
Collected at T5: 12 months after delivery
Title
T5 Dosage received - time spent on MENTAL HEALTH component
Description
Time spent on MENTAL HEALTH component (hours and minutes)
Time Frame
Collected at T5: 12 months after delivery
Title
Fidelity at T1
Description
This is an assessment of the researcher in the team to check on the research dietitian's in delivering group support according to a pre-specified plan. This will be reported descriptively.
Time Frame
collected at T1: 36 weeks pregnancy
Title
Fidelity at T3
Description
This is an assessment of the researcher in the team to check on the research dietitian's in delivering group support according to a pre-specified plan. This will be reported descriptively.
Time Frame
collected at T3: 6 months after delivery
Title
Fidelity at T5
Description
This is an assessment of the researcher in the team to check on the research dietitian's in delivering group support according to a pre-specified plan. This will be reported descriptively.
Time Frame
collected at T5: 12 months after delivery
Title
Semi-structured interview at T1
Description
Interviews on participant experiences and satisfaction towards the intervention
Time Frame
Collected at T1: 36 weeks pregnancy
Title
Semi-structured interview at T3
Description
Interviews on participant experiences and satisfaction towards the intervention
Time Frame
Collected at T3: 6 months after delivery
Title
Semi-structured interview at T5
Description
Interviews on participant experiences and satisfaction towards the intervention
Time Frame
Collected at T5: 12 months after delivery
Title
Mother infant relationship at T2
Description
3-minutes video recording captured through Zoom and coded based on the CARE-INDEX
Time Frame
Collected at T2: 3 months after delivery
Title
Satisfaction survey at T5
Description
acceptability, experience and perceived usefulness of the project
Time Frame
Collected at T5: 12 months after delivery
Title
Hypertension
Description
This is a diagnosis by the clinic and reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Hypercholesterolemia
Description
This is a diagnosis by the clinic and reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Delivery method
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Pregnancy complications
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Birth complications
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Breastfeeding status on discharge
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Neonatal birth weight
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Neonatal APGAR score 5 minutes
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Congenital anomaly
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Congenital pnuemonia / heart defects
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Admission to neonatal intensive care
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
Title
Length of stay at the hospital ward
Description
This is reported in the record from anytime after delivery to 3 months postpartum.
Time Frame
Collected at T2: 3 months postpartum
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
only FEMALE.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
aged above 18 years,
diagnosed with GDM defined using fasting blood glucose > 5.1mmol/1 or 2-hour postprandial >7.8mmol/1 which are the standard guidelines for diagnosis of GDM in Malaysia,
permanent resident in the state of Selangor,
registered in one of the study health clinics
owning a smartphone (iOS 11 or Android 7) with internet connection,
able to speak, read, and understand English and/or Malay.
Exclusion Criteria:
are having a twin pregnancy,
have type 1 or 2 diabetes,
have severe physical disability that would prevent any increased uptake of physical exercise,
have severe mental illness (psychosis, bipolar, substance dependence or active suicidal ideation),
are currently participating in a weight loss program or diabetes prevention intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BOON HOW CHEW
Phone
0126900652
Email
chewboonhow@upm.edu.my
First Name & Middle Initial & Last Name or Official Title & Degree
IKLIL IMAN MOHD SA'ID
Email
iklil17493@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
BOON HOW CHEW
Organizational Affiliation
Universiti Putra Malaysia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
KHALIDA ISMAIL
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinik Kesihatan Puchong Batu 14
City
Petaling Jaya
State/Province
Selangor
ZIP/Postal Code
47100
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haslinda Hassan
Phone
0122146257
Email
lynn_nidz@yahoo.com.my
First Name & Middle Initial & Last Name & Degree
Atikah Mohamed Basri
Phone
0134495057
Facility Name
Klinik Kesihatan Seri Kembangan
City
Seri Kembangan
State/Province
Selangor
ZIP/Postal Code
43300
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ziti Akthar Supian
Phone
0136813478
Email
zitisupian@gmail.com
First Name & Middle Initial & Last Name & Degree
Fadzilah Abd Rahman
Phone
0192257783
Facility Name
Klinik Kesihatan Putrajaya Presint 9
City
Putrajaya
State/Province
Wilayah Persekutuan
ZIP/Postal Code
62250
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wan Noor Azlin
Phone
0133932688
Email
drwanazlin@moh.gov.my
First Name & Middle Initial & Last Name & Degree
Noor Zaehan Hani
Phone
0132726352
Email
zaehanzolkiply@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
Citation
Mohd Sa'id, I. I., Papachristou Nadal, I., Forbes, A., Goldsmith, K., Ismail, I. Z., Hassan, F., Ching, S. M., Guess, N., Murphy, H., Prina, M., Mohd Yusoff, B. N., Basri, N. I., Binti Salim, M. S., Mahamad Sobri, N. H., Har Yap, P. P., Ismail, K., & Chew, B. H. (2021). A Protocol of Process Evaluations of Interventions for the Prevention of Type 2 Diabetes in Women With Gestational Diabetes Mellitus: A Systematic Review. International Journal of Qualitative Methods, 20. https://doi.org/10.1177/16094069211034010
Results Reference
background
PubMed Identifier
34446477
Citation
Sobri NHM, Ismail IZ, Hassan F, Papachristou Nadal I, Forbes A, Ching SM, Ali H, Goldsmith K, Murphy H, Guess N, Mohd Yusof BN, Basri NI, Salim MS, Azmiyaty C, Mohd Sa'id II, Chew BH, Ismail K; MYGODDESS Project Team. Protocol for a qualitative study exploring the perception of need, importance and acceptability of a digital diabetes prevention intervention for women with gestational diabetes mellitus during and after pregnancy in Malaysia (Explore-MYGODDESS). BMJ Open. 2021 Aug 26;11(8):e044878. doi: 10.1136/bmjopen-2020-044878.
Results Reference
background
PubMed Identifier
36074545
Citation
Benton M, Iman I, Goldsmith K, Forbes A, Ching SM, Papachristou Nadal I, Guess N, Murphy HR, Mohd Yusof BN, Baharom A, Mahamad Sobri NH, Basri NI, Salim MS, Ismail IZ, Hassan F, Ismail K, Chew BH. A Mobile Phone App for the Prevention of Type 2 Diabetes in Malaysian Women With Gestational Diabetes Mellitus: Protocol for a Feasibility Randomized Controlled Trial. JMIR Res Protoc. 2022 Sep 8;11(9):e37288. doi: 10.2196/37288.
Results Reference
background
Links:
URL
https://gtr.ukri.org/projects?ref=MR%2FT018240%2F1
Description
UKRI website about the project
Learn more about this trial
The MalaYsian GestatiOnal Diabetes and Prevention of DiabetES Study
We'll reach out to this number within 24 hrs